Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) has completed the conversion of 1,157,778 domestic shares and unlisted foreign shares into H shares on Tuesday, a same-day bourse filing said.
The listing of the converted H Shares on the Hong Kong bourse will begin Sept. 19.
The shares, which represent 0.52% of the company's issued share capital following the conversion and listing, are held by two participating shareholders.
Shares of the biopharmaceutical company closed 1% higher on Tuesday.
Price (HKD): $187.00, Change: $+1.9, Percent Change: +1.03%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments